摘要
目的：探讨顺铂联合吉西他滨与顺铂联合紫杉醇治疗晚期非小细胞肺癌的疗效。方法选择我院2012年1月~2014年1月我院收治的非小细胞肺癌患者100例，随机分为观察组（吉西他滨＋顺铂，GP组）和对照组（紫杉醇＋顺铂，TP组），每组50例，两组患者均每21天为一个周期，连用2个周期以上后观察疗效，比较两组的毒副反应。结果观察组治疗后的有效率达42.0%（21/50），高于对照组的有效率40%（20/50），但组间比较差异无统计学意义（P＞0.05）。观察组、对照组的Ⅲ＋Ⅳ度白细胞减少率比较，差异存在显著性（8%vs 30%，P〈0.05）。观察组、对照组的Ⅲ＋Ⅳ度血小板减少率比较，差异存在显著性（22%vs 4%，P〈0.05）。观察组和对照组血红蛋白下降、恶心呕吐、脱发、肝功能损害、肾功能损害的发生率比较，差异无统计学意义（P＞0.05）。结论顺铂联合吉西他滨与顺铂联合紫杉醇治疗晚期非小细胞肺癌的疗效相似，毒副作用各异且均可耐受，均为治疗晚期非小细胞肺癌效果较好的治疗方案。
Objective To investigate the curative effect of cisplatin combined with gemcitabine and cisplatin plus pacli-taxel in the treatment of advanced non-small cell lung cancer. Methods All 100 patients with non-small cell lung can-cer in our hospital from January 2012 to January 2014 in our hospital, randomly divided into observation group （gemc-itabine＋cisplatin, GP group） and control group （paclitaxel＋cisplatin, TP group）, each group had 50 cases, two groups of patients every 21 days for a cycle, observed curative effect after 2 cycles, toxic and adverse reaction were compared between the two groups. Results The effective rate of the observation group after treatment was 42.0%（21/50）,was higher than that of the control group 40% （20/50）, but there was no significant difference （P＆gt;0.05）. Conclusion Cura-tive effect of cisplatin combined with gemcitabine and cisplatin plus paclitaxel in the treatment of advanced non-small cell lung cancer is similar, the poisonous side effect is different and can be tolerated, for the treatment of advanced non-small cell lung cancer treatment plan better.
出处
《中国现代医生》
2015年第3期74-76,共3页
China Modern Doctor
关键词
非小细胞肺癌
晚期
顺铂
吉西他滨
紫杉醇
Non-small cell lung cancer
Advanced
Cisplatin
Gemcitabine
Paclitaxel
